Bal is an experienced patent attorney and has worked within the pharmaceutical field for over 20 years. He has a strong technical background and has held senior roles within both the R&D and IP functions of global pharmaceutical and drug delivery companies.
During his career he has built and defended patent portfolios protecting products at all stages of development, including a range of high-profile on-market medicines.
Bal has a first degree in Pharmacy and a PhD in drug delivery and started his career with AstraZeneca as a senior product development scientist. During his time in this role, he led several technical programs to develop and repurpose drug candidates and is an inventor on patents protecting one of AZ’s oncology medicines.
In 2006, Bal transitioned into the IP department of AZ and progressed to the role of senior patent attorney. He has managed global patent portfolios protecting key products and he has also led IP due diligence activities for licensing and late-stage acquisitions. During his last 3 years at AZ, Bal was seconded into the litigation group to defend patents protecting a CNS product in multiple jurisdictions across Europe, South America and Asia.
Bal has developed an in-depth knowledge of the strategic aspects of multi-jurisdictional pharmaceutical patent litigation and also regularly acts as lead counsel in European patent opposition and appeal proceedings.
Since joining HGF, Bal has used his patent expertise and understanding of drug discovery and development to help clients focus their IP activities and achieve their commercial objectives.
Biopharmaceutics and Drug Delivery
March 14th 2019
Visiting lecturer at King’s College London and contribute to drug development modules of MPharm Pharmacy degree course.
Mentoring trainee patent attorneys.
Previously lectured on JDD course for EQE qualifications.
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.